Tandem Diabetes Care (TNDM) Cash & Equivalents (2013 - 2026)

Tandem Diabetes Care has reported Cash & Equivalents for 14 years, with the latest figure at $179.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 234.72% year-over-year to $179.3 million; the trailing twelve-month figure through Mar 2026 stood at $179.3 million (up 234.72% YoY), and the FY2025 full-year result was $90.6 million, up 30.91% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $179.3 million, up from $90.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $179.3 million in Q1 2026, with the low at $47.7 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $94.5 million across 5 years, with a median of $90.6 million in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 65.88% — and 2026, when it surged 234.72%.
• Tandem Diabetes Care's Cash & Equivalents stood at $172.5 million in 2022, then sank by 65.88% to $58.9 million in 2023, then advanced by 17.61% to $69.2 million in 2024, then soared by 30.91% to $90.6 million in 2025, then surged by 97.86% to $179.3 million in 2026.
• The last three Cash & Equivalents figures came in at $179.3 million (Q1 2026), $90.6 million (Q4 2025), and $91.9 million (Q3 2025), per Business Quant data.